Thanks, Taz! I had a wrong impression about Sanofi's inhibitor being in the market . It's Novortis and not Sanofi! Thanks for correcting me.
Dr. Silverman IS from NY City!! What do you expect when he is so close to Wall Street and perhaps other vested interests to which rise of Imetelstat is a death nail? Is Cornell not under the influence of its funds contributors?
verify if Sanofi has hired agents in Wall Street to help keep the Geron share price below $5.00!! This will result in a difficulty for Geron to raise more money. Doing so and postponing licensing of Imtelstat even for as little as a month means Sanofi pockets approx $20M through extended sale of its JAK inhibitor!! Do you think big pharmas are playing such games?
What did the FDA do with this info? Ignore and give license to Sanofi? Sanofi does have its influence at the FDA, isn't it?
Yes, Taz, I will not deny that; but, I meant institutional investors, not institutional traders like hedge funds. Also, hedge funds using HFT can be is a substantial market manipulator and monkey-action initiator, perhaps making the MM often nervous!! These things will go on until institutional rush crushes those or minimze that influence.
Thanks for posting useful and meaningful thoughts. That's what this board should be meant to be used, not for posting rubbish and half-truths.
In my view, Geron has no choice but to get into a partnership or a compatible merger. But, it will be to the best advantage of shareholders if that is done after taking up Ph III trial for MF. Until then, the company has the right size and resources to continue. If the management succeeds in getting accelerated-trial statusfor MF from the FDA (which I am sure it's doing all it can), the time to arrive at that stage will be much shorter than we think. Perhaps, the FDA may advise the management to do so too for the benefit of the medical science and practice. However, the company must build up preliminaries for possible wider applications of Imetelstat, wisely using available resources before accepting any merger deal .
I call traders who hop in and out upon assumed signals on minute-by-minute basis, just like monkeys can never sit quiet. I wonder how many of them really make money in the end! Of course, some smart ones do make a bundle occasionally; but, the rest come empty handsin the end or be sore loosers. Yet, they do not give up!!!
Thanks boy! I stayed away but kept reading what some significant posters like you, ETW, Taz, Black, etc. had posted so far; and, will keep doing so. Especially, I liked some knowledgeable medically significant discussions held herein by certain posters. But, I have decided to indulge to a much lesser extent than I did in the past out of disgust for predomionence of so many others on this board that chew out trash!! Yes, I was very critical of Scarlett and Huh last year but do not think I was fair then!! Well, to opine without having ability or resources to know the complete inside story is always premature! I realized that for myself!!!
Black, perhaps you are forgetting that neither Scarlett nor Huh is a Wall Street guy like Gary Rabin of ACTC; they are both scientists/doctors with a small research-outfit management experience, lacking sensitivity to daily share-price movement. They both are in to get the company to a final destination that, I think, they are doing well. Note that, unlike so many other small biotechs, they have managed a decent cash position and kept the company debt-free and will maintain that condition until Ph III for the MF trial is reached. I can't say they have mismanaged!!
Black, to judge appropriately what and why did the Geron management did what it deed, you have to be in the board! Getting rid of controversial hESC side and concentrating on the future of Imetelstat that looked disasterous last year to us doesn't seem right anymore. Expulsion of Okarma followed by trimming the other staff, including the CFO Cooper and putting Huh as COB, should be kept in mind before we judge the past actions and extrapolate the company's immediate future. To me now, accordingly, company's future doesn't look bad at all. In fact, it looks like a well-thought out plan. Just be a trader for the next few quarters (at the most) and then be a long, if you do not want to be a long now.
and institutions staying out until some significant news develops. MM will do his job to maximize his business. However, the company is moving ahead solidly and step-by-step to be a formidable entity in the oncology arena. Imetelstat has to be brought to the market ASAP for myeloid applications before applications to other cancers are searched actively by the company. Can the company do it alone? I doubt because it doesn't have the marketing ability nor the managing ability for such a global commercial operation. It has to find a partner or get merged with a pharma with wide shoulders. Doing so with an outfit like Amgen or Biogen would have been in the current management's plan, perhaps after reaching Ph III for the MF trial by the company so that a best deal can be reached. Until then, longs need to be patient and, the monkeys have the ground to play their games as dictated by the MM. When things become clear to the MM (secretly), he will lead the share price consistently above $5 to lure institutional players. Then, the monkeys' game will be over for ever!!!